Drug Profile

DE 120

Alternative Names: DE-120

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Santen Incorporated
Developer Santen Inc
Class Eye disorder therapies
Mechanism of Action Platelet-derived growth factor inhibitors; Vascular endothelial growth factor A inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Aug 2017 Discontinued - Phase-II for Wet age-related macular degeneration in USA (Intravitreous) (Santen Pipeline, August 2017)
31 Oct 2016 Santen completes a phase II trial in Wet age-related macular degeneration in USA (Intravitreous) (NCT02401945)
21 Apr 2016 Santen completes a phase II trial in Wet age-related macular degeneration in USA (NCT02022501)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com